National Bank of Canada’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Other funds holding ALNY
VPM
VCM
National Bank of Canada's ALNY Position: Q1 2026 in Review
National Bank of Canada reduced its Alnylam Pharmaceuticals (ALNY) stake by 4.3% in Q1 2026, selling an estimated $962K and leaving 63,607 shares worth $21M. The position accounts for 0.02% of the portfolio, ranked #480.
National Bank of Canada first reported a position in ALNY in Q4 2021 and has held it in 18 quarters since. The position peaked at $26.4M in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- National Bank of Canada held 63,607 shares of Alnylam Pharmaceuticals worth $21M as of Q1 2026.
- National Bank of Canada sold 2,826 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $962K.
- Alnylam Pharmaceuticals made up 0.02% of National Bank of Canada's portfolio in Q1 2026, its #480 holding.
- National Bank of Canada first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
- National Bank of Canada's Alnylam Pharmaceuticals position peaked at $26.4M in Q4 2025.
- 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.